We bring you the latest news from the healthcare about the health care in the United Kingdom.

woensdag 13 september 2017

The Lancet: [Viewpoint] Saving an additional 100 million lives

[Viewpoint] Saving an additional 100 million lives
10 years ago, we suggested a way to prevent 100 million deaths from tobacco.1 That initiative, grounded on the WHO Framework Convention on Tobacco Control, led to the creation of the MPOWER technical package, which in the past decade has newly protected about 3·5 billion people with effective tobacco control strategies, reduced tobacco use prevalence substantially, and prevented 30 million deaths.2,3 As that work continues, today, along with global partners, we are launching a new cardiovascular health initiative—Resolve—to prevent an additional 100 million deaths globally.
Read more

[Global Health Metrics] Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016
GBD 2016 provides an updated and expanded evidence base on where the world currently stands in terms of the health-related SDGs. Our improved measure of UHC offers a basis to monitor the expansion of health services necessary to meet the SDGs. Based on past rates of progress, many places are facing challenges in meeting defined health-related SDG targets, particularly among countries that are the worst off. In view of the early stages of SDG implementation, however, opportunity remains to take actions to accelerate progress, as shown by the catalytic effects of adopting the Millennium Development Goals after 2000.
Read more

[Articles] Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
To the best of our knowledge, ramucirumab plus docetaxel is the first regimen in a phase 3 study to show superior progression-free survival over chemotherapy in patients with platinum-refractory advanced urothelial carcinoma. These data validate inhibition of VEGFR-2 signalling as a potential new therapeutic treatment option for patients with urothelial carcinoma.
Read more

[Comment] Antiangiogenesis to curb urothelial cancer
Angiogenesis has been associated with clinicopathological factors and features of biological aggressiveness in urothelial cancer.1,2 Although several agents targeting the vascular endothelial growth factor (VEGF) pathway have been investigated in phase 1 and 2 trials in advanced urothelial cancer and as maintenance,1,3–5 the overall clinical benefit has been small, with occasional disease stabilisation seen in some patients.1,3
Read more

[Articles] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Across all primary analysis groups, rucaparib significantly improved progression-free survival in patients with platinum-sensitive ovarian cancer who had achieved a response to platinum-based chemotherapy. ARIEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance treatment setting versus placebo could be considered a new standard of care for women with platinum-sensitive ovarian cancer following a complete or partial response to second-line or later platinum-based chemotherapy.
Read more